Basit öğe kaydını göster

Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

dc.contributor.authorTIRIBELLI, M
dc.contributor.authorEskazan, AHMET EMRE
dc.date.accessioned2021-03-02T20:52:59Z
dc.date.available2021-03-02T20:52:59Z
dc.identifier.citationEskazan A. E. , TIRIBELLI M., "Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?", Leukemia research, cilt.74, ss.55-56, 2018
dc.identifier.issn0145-2126
dc.identifier.othervv_1032021
dc.identifier.otherav_04250a4f-f957-4227-9f14-d58c95a6a741
dc.identifier.urihttp://hdl.handle.net/20.500.12627/8731
dc.identifier.urihttps://doi.org/10.1016/j.leukres.2018.09.013
dc.language.isoeng
dc.titleDoes switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?
dc.typeMakale
dc.relation.journalLeukemia research
dc.contributor.department, ,
dc.identifier.volume74
dc.identifier.startpage55
dc.identifier.endpage56
dc.contributor.firstauthorID180466


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster